



Insights Into Multiple Myeloma

August 12, 2020

Speaker: Keith Stewart, MB, ChB

Moderator: Sushil Bhardwaj, MD, FACP

AGENDA

Time (EST)	Topic
6.00 PM – 6.15 PM (15 min)	Introduction <ul style="list-style-type: none"> • Program overview • Baseline ARS questions
6.15 PM – 7.15 PM (30-min presentation; 30-min discussion)	Treatment of Newly Diagnosed Multiple Myeloma <ul style="list-style-type: none"> • Overview of current data <ul style="list-style-type: none"> – Risk stratification – Selection of induction therapy for transplant-eligible and -ineligible patients – Incorporation of 4-drug regimens <ul style="list-style-type: none"> ▪ Dara-KRd – Transplant: eligibility, timing – Maintenance therapy: which patients, which agents (lenalidomide, bortezomib, now ixazomib?), for how long? – Evolving role of MRD in multiple myeloma • Reaction and discussion
7.15 PM – 7.30 PM (15 min)	Break
7.30 PM – 8.10 PM (20-min presentation; 20-min discussion)	Treatment of Patients in Early Relapse <ul style="list-style-type: none"> • ARS questions • Overview of current data <ul style="list-style-type: none"> – What is the optimal approach for patients progressing after 1 prior line of therapy? <ul style="list-style-type: none"> ▪ How are/will 3-drug combinations with mAbs vs proteasome inhibitors (or both) being incorporated into practice? <ul style="list-style-type: none"> • CANDOR trial (KdD vs Kd) ▪ Existing data (RVd, KRd, IRd, ERd, EVd) and new results (eg, PVd) ▪ Differentiation among PIs: bortezomib, carfilzomib, ixazomib – Optimal integration of mAbs: elotuzumab, daratumumab <ul style="list-style-type: none"> ▪ Impact of prior therapy, depth and duration of prior response • Reaction and discussion
8.10 PM – 8.50 PM (20-min presentation; 20-min discussion)	Treatment of Patients in Later Relapse <ul style="list-style-type: none"> • ARS questions • Overview of current data <ul style="list-style-type: none"> – Approach to treatment of patients progressing after ≥ 2 prior regimens <ul style="list-style-type: none"> ▪ Impact of prior therapy on selection among pomalidomide, daratumumab, or other

	<ul style="list-style-type: none"> ▪ Weekly vs twice-weekly carfilzomib plus dexamethasone ▪ Incorporation of selinexor and venetoclax – Impact of prior treatment, patient characteristics, and residual toxicities – Focus on emerging options: immune checkpoint inhibitors, CAR T therapy, bispecific antibodies? • Reaction and discussion
<p>8.50 PM – 9.00 PM (10 min)</p>	<p>Key Takeaways and Meeting Evaluation</p>